Home Visit
Upload
AFB Drug Susceptibility Panel 2nd Line (4 Drugs) KEPO By MGIT - Pure Culture
Also known as: AFB Drug Susceptibility Panel - 2nd Line (4 drugs) KEPO, Pure Culture
No special precautions
Sample Type
Blood
Recommended for
Male, Female
Report
Within 24 Hours
Blood test at Home
NABL & CAP Accredited Labs
Accurate & Quality Test Reports
Trusted by Leading Doctors & Hospitals
Second-Line Anti-Tuberculosis Drug Susceptibility Test Overview
The "AFB Drug susceptibility - 2nd Line (4 Drugs) KEPO panel by MGIT - Pure Culture" test is a vital diagnostic tool used for tuberculosis (TB) treatment. It utilizes the MGIT (Mycobacteria Growth Indicator Tube) method on pure cultures of Mycobacterium tuberculosis (MTB) Complex to assess the drug susceptibility of MTB to four second-line anti-tuberculosis drugs: Kanamycin, Ethionamide, para-aminosalicylic acid (PAS), and Ofloxacin, collectively known as the KEPO panel. The clinical utility of this test lies in providing essential information to healthcare professionals about the effectiveness of these drugs against the MTB Complex causing TB, particularly in drug-resistant cases. By identifying drug resistance early, clinicians can develop personalized and effective treatment regimens, ensuring optimal care and increasing the chances of successful TB treatment. Overall, this test significantly contributes to managing drug-resistant TB cases and improving patient outcomes, supporting the ongoing efforts to combat tuberculosis effectively.
The AFB (Acid-Fast Bacilli) Drug Susceptibility Panel 2nd Line (4 Drugs) KEPO By MGIT - Pure Culture is a laboratory test that assesses the susceptibility of Mycobacterium tuberculosis to second-line anti-tuberculosis drugs. This test uses the Mycobacteria Growth Indicator Tube (MGIT) system, an automated method for culturing and performing drug susceptibility testing on mycobacteria. The panel typically includes four drugs: amikacin, kanamycin, capreomycin, and a fluoroquinolone such as levofloxacin or moxifloxacin.
The Second-Line Anti-Tuberculosis Drug Susceptibility Test is crucial for identifying drug-resistant tuberculosis (TB), particularly multi-drug-resistant (MDR) TB, where the bacteria are resistant to the two most potent first-line anti-TB drugs, isoniazid and rifampicin. By determining the susceptibility of the TB strain to second-line drugs, this test guides the selection of appropriate treatment regimens.
Reasons for Undergoing the Second-Line Anti-Tuberculosis Drug Susceptibility Test
There are several key reasons for undergoing the Second-Line Anti-Tuberculosis Drug Susceptibility Test:
- To identify multi-drug-resistant (MDR) TB, where the bacteria are resistant to at least isoniazid and rifampicin
- To guide the selection of appropriate second-line anti-TB drugs for patients with MDR-TB or those who have failed first-line treatment
- To ensure that patients receive effective treatment, improving outcomes and reducing the spread of drug-resistant TB
- To monitor the emergence of drug resistance during treatment and adjust the regimen accordingly
List of Parameters Considered During the Second-Line Anti-Tuberculosis Drug Susceptibility Test
The Second-Line Anti-Tuberculosis Drug Susceptibility Test measures the susceptibility of Mycobacterium tuberculosis to the following four second-line anti-tuberculosis drugs:
- Kanamycin: An aminoglycoside antibiotic used to treat TB. The test determines whether the MTB is susceptible or resistant to this drug.
- Ethionamide: A thioamide antibiotic used as a second-line drug for TB. The test assesses the effectiveness of this drug against the MTB.
- Para-aminosalicylic acid (PAS): An antibiotic used in combination with other drugs to treat TB. The test evaluates the susceptibility of MTB to PAS.
- Ofloxacin: A fluoroquinolone antibiotic used as a second-line drug for TB. The test determines the effectiveness of this drug in treating the specific MTB strain.
Second-Line Anti-Tuberculosis Drug Susceptibility Test Preparation
Preparing for the Second-Line Anti-Tuberculosis Drug Susceptibility Test involves the following steps:
- Inform Your Healthcare Provider: Discuss any medications you are currently taking, including antibiotics, with your doctor.
- Provide Medical History: Share your complete medical history and any previous TB treatment details with your doctor.
- No Fasting Required: Fasting is not necessary for this test, as it does not affect the results or the sample collection process.
- Ensure Correct Sample Collection: Follow your doctor's instructions carefully to ensure the correct collection of the sample, as this is crucial for obtaining accurate test results.
Second-Line Anti-Tuberculosis Drug Susceptibility Test Results & Interpretation
The interpretation of the results of the Second-Line Anti-Tuberculosis Drug Susceptibility Test are as follows:
- Susceptible: If the MTB is reported as susceptible to a particular drug, it means that the drug can be effectively used in the treatment regimen to combat the infection.
- Resistant: If the MTB is reported as resistant to a specific drug, it indicates that the drug may not be effective in treating the infection, and alternative treatments should be considered.
- Interpretation: The results of this Second-Line Anti-Tuberculosis Drug Susceptibility Test should always be interpreted by a qualified doctor in the context of the patient's overall health status, medical history, and other diagnostic information to develop the most appropriate treatment plan.
Home Collection for Second-Line Anti-Tuberculosis Drug Susceptibility Test
While home sample collection is generally not available for the Second-Line Anti-Tuberculosis Drug Susceptibility Test, as it requires a pure culture of M. tuberculosis typically obtained and processed in a laboratory setting, Metropolis Healthcare is committed to making healthcare accessible and providing quality diagnostic solutions. With a network of state-of-the-art laboratories and a team of skilled professionals, Metropolis Healthcare ensures accurate and timely results for all its tests, including the Second-Line Anti-Tuberculosis Drug Susceptibility Test. By adhering to the highest standards of sample handling and testing, Metropolis Healthcare delivers reliable results that enable doctors to make informed decisions and provide the best possible care to their patients.
AFB Drug Susceptibility Panel - 2nd Line (4 drugs) KEPO, Pure Culture Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the AFB Drug Susceptibility Panel - 2nd Line (4 drugs) KEPO, Pure Culture with a clear pricing structure.
The AFB Drug Susceptibility Panel - 2nd Line (4 drugs) KEPO, Pure Culture Price in Mumbai is ₹ 6,150 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
This test measures the susceptibility of Mycobacterium tuberculosis (Mtb) complex to four drugs: kanamycin, ethionamide, para-aminosalicylic acid (PAS), and ofloxacin.
• To assess the effectiveness of second-line drugs in treating tuberculosis
• To identify drug resistance and guide the selection of appropriate medications
• To monitor treatment progress and adjust medication regimens accordingly
• To prevent the development of drug resistance by ensuring effective treatment
This test is recommended when • standard first-line tuberculosis treatment fails or is not tolerated, • drug-resistant tuberculosis is suspected or confirmed, • medication side effects appear or persist, or • monitoring treatment response and adjusting medications for individual patient needs.
Abnormal results indicate resistance to one or more drugs, requiring alternative treatment options.
During this test, a healthcare professional will collect a sample of the Mycobacterium tuberculosis (Mtb) complex from your body. They will send the sample for analysis using the MGIT (Mycobacteria Growth Indicator Tube) method.
• Provide your complete medical history and any previous tuberculosis treatment details.
• Follow any specific instructions given by your healthcare provider, such as fasting requirements or discontinuing certain medications.
• Inform your doctor if you have any specific requirements.
• Acid-Fast Bacillus (AFB) Smear and Culture: This test helps diagnose tuberculosis by detecting the presence of acid-fast bacilli in a patient's sample.
• GeneXpert MTB/RIF: This molecular test detects the presence of Mtb complex DNA as well as resistance to rifampicin, a first-line tuberculosis drug.
Second-Line Anti-Tuberculosis Drug Susceptibility Test or Second-Line DST for Tuberculosis
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis bacteria. It primarily affects the lungs but can also affect other parts of the body. Common symptoms include coughing, fever, weight loss, and fatigue.
The Second-Line Anti-Tuberculosis Drug Susceptibility Test is a laboratory test that determines the susceptibility of Mycobacterium tuberculosis to second-line anti-tuberculosis drugs. It is crucial for managing multi-drug-resistant tuberculosis and guiding the selection of appropriate second-line drugs for effective treatment.
Home sample collection is available for the Second-Line Anti-Tuberculosis Drug Susceptibility Test.
The Second-Line Anti-Tuberculosis Drug Susceptibility Test does not measure levels but rather categorises the bacteria as susceptible or resistant to each drug. The interpretation is based on the presence or absence of bacterial growth when exposed to specific drug concentrations.
The Second-Line Anti-Tuberculosis Drug Susceptibility Test is used to determine the effectiveness of second-line anti-tuberculosis drugs against M. tuberculosis, particularly in cases of multi-drug-resistant tuberculosis or when first-line treatment has failed.
Testing should be done when there is a suspicion of multi-drug-resistant tuberculosis or when the patient remains culture-positive after three months of treatment.
There is no specific time requirement for the Second-Line Anti-Tuberculosis Drug Susceptibility Test, as it involves culturing and testing bacterial isolates.
No, fasting is not required for the Second-Line Anti-Tuberculosis Drug Susceptibility Test.
It is crucial to ensure that the sample is handled and transported correctly to maintain its viability and purity. Additionally, providing an accurate treatment history is essential for interpreting the results correctly.
The Second-Line Anti-Tuberculosis Drug Susceptibility Test typically includes four second-line drugs: amikacin, kanamycin, capreomycin, and a fluoroquinolone such as levofloxacin or moxifloxacin. The susceptibility or resistance of the bacteria to each drug is determined.
The Second-Line Anti-Tuberculosis Drug Susceptibility Test should be performed when there is a suspicion of multi-drug-resistant tuberculosis, when the patient remains culture-positive after three months of treatment, or when there are signs of treatment failure with first-line drugs.
The time required for the Second-Line Anti-Tuberculosis Drug Susceptibility Test may vary depending on the laboratory and the specific testing method used.
The reports for the Second-Line Anti-Tuberculosis Drug Susceptibility Test can typically be available within 4 weeks, based on the day/time when the sample was collected and processed. For the exact turnaround time, you can consult with your healthcare provider or the specific lab.
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
WhatsApp